

Management of IIIA (N2) Non-Small Cell Lung Cancer

Notes:

* Preferred chemotherapy regimen is cisplatin/etoposide. Carboplatin/paclitaxel is a viable alternative if borderline performance status or medical comorbidities preclude cisplatin based therapy.

** All Patient's being considered for trimodality therapy should be discussed at a multidisciplinary tumor board before initiating therapy.

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65

